The central stock price target of $17.50 is the arithmetic mean of three verified analyst price targets reviewed for InfuSystem Holdings, Inc. (INFU) , a U.S. healthcare services provider listed on NYSE American. With the latest verified price near $14.68 , reaching the target would require a move of roughly 19% .
INFU slipped -1.63% during regular market hours, easing from a $14.68 prior close to $14.44. No verified news or fundamental catalyst found to explain today's move. The drop is likely mild profit-taking after the prior session's +7.23% surge, consistent with the stock's roughly 2% typical daily swing.
SENS shares jumped from Monday's $9.80 close to $11.925, up +21.73%, during Tuesday's regular trading session. The surge extends a post-earnings rally sparked by Monday evening's Q3 report: record revenue of $19.6M (+140% year-over-year, roughly 19% above estimates) and a third full-year guidance raise to $68M-$70M.
The central $13 stock price target is the arithmetic mean of six verified analyst price targets, rounded from roughly $13.33; the range spans $10 to $18. With shares around $9.80 as of early November 2026, reaching $13 would require a roughly 33% advance — a substantial move, not a trivial one.
The $2.30 central target is the arithmetic mean of three verified analyst price targets: $4.00, $1.90, and $1.00. The latest verified price is approximately $1.37, implying an upside of about 68% to reach $2.30.
QSI fell from a $1.37 prior close to about $1.27, a -7.31% decline, during regular market hours. No verified news or fundamental catalyst found; the drop is likely profit-taking after a sharp multi-week rally, consistent with a micro-cap that typically swings about 6% a day.
The $11.30 central target is the arithmetic mean of three verified analyst price targets ($10, $11, and $13), rounded from approximately $11.33. The stock recently traded near $5.46, meaning the target implies roughly 107% upside — a very large move from current levels.
LENSAR (LNSR) shares fell -14.47% during regular trading hours, dropping from a prior close of $5.46 to $4.67. The decline followed this morning's Q3 2026 earnings, which missed consensus — GAAP EPS of -$0.38 versus a -$0.09 estimate and revenue of $14.13M versus $14.29M expected.
UFPT slipped -1.28% during regular market hours, easing from a $318.86 prior close to $314.77. No verified news or fundamental catalyst found. The dip is consistent with routine consolidation and profit-taking after the stock's sharp post-earnings swings, including a +17.7% surge on Nov 4 following strong Q3 results.
BWAY fell -6.27% during regular trading hours, dropping from the prior close of $11.64 to $10.91. The decline followed Q3 earnings, where GAAP EPS of $0.05 missed the $0.09 consensus by $0.04, even as revenue of $18.1M (+34% YoY) beat estimates and full-year guidance was raised to the upper end.
TLSI dropped from a prior close of $3.22 to $2.53, down -21.43%, during regular market hours. The decline followed Q3 2026 results: EPS of -$0.15 missed the -$0.12 estimate, revenue of $12.9M missed the $14.31M consensus, and FY2026 revenue guidance was cut to $46M-$48M versus ~$53M expected.
The central $10 stock price target is the arithmetic mean of five verified analyst price targets I collected (rounded from $10.40), not a single analyst's view. The latest verified price is approximately $3.22, meaning reaching $10 would require a roughly 210% gain — a very large move.
Myomo reported third-quarter 2026 revenue of $12.33 million, up about 22% from $10.09 million a year earlier and above the consensus estimate of roughly $11.5 million. Gross margin expanded to 71.3%, up from 63.8% in the prior-year quarter, helped by a higher average selling price and lower material costs.
The central target of $2.00 is the arithmetic mean of four verified, current analyst price targets, rounded from $2.025. The reviewed targets range from a low of $1.60 (B. Riley Securities) to a high of $2.50 (Lake Street), with all four analysts rating the stock a Buy.
Hyperfine reported record third quarter 2026 revenue of $6.0 million, up 73% year over year and 53% sequentially. Net loss narrowed to $0.06 per share, beating the consensus estimate of a $0.08 loss.
The central target of $10.50 reflects the arithmetic mean of analyst price targets across roughly 11 to 16 covering firms, though the range is extraordinarily wide at approximately $4 to $18 . Perspective Therapeutics, Inc. (CATX) recently traded near $0.86 , meaning the target implies a move of more than 1,100% — a "very large" gap that underscores how far the shares have fallen from their 52-week high of $6.16.
Perspective Therapeutics reported a third-quarter 2026 net loss of $32.4 million, or $0.27 per basic and diluted share, compared with a net loss of $26.0 million, or $0.35 per share, in the same period a year earlier. The company's reported loss per share of $0.27 came in below the consensus estimate of roughly $0.24, while grant revenue of $20,000 also fell short of analyst expectations.
The central target of $4.00 reflects a publicly discussed price objective—a prior analyst target level and round-number threshold—not a current analyst consensus; the average of three current targets sits below the latest price. With a recent close near $3.38, reaching $4.00 would require a rise of roughly 18%.
Third-quarter revenue of $35.0 million beat the consensus estimate of roughly $33.85 million, though it declined about 13% from $40.2 million in the year-ago period. GAAP (Generally Accepted Accounting Principles) net loss per share narrowed to $0.46 from $0.73 a year earlier, while adjusted (non-GAAP) loss per share of $0.46 came in slightly wider than the $0.43 consensus.
The central target of $13 is the arithmetic mean of six current, individually attributed analyst price targets reviewed for this analysis, with a low-to-high range of roughly $9 to $18. At the latest verified close near $9.80, reaching $13 would require a move of approximately 33%, a substantial gain but well within the span analysts already publish.